Fang Zhou, MD
Family Medicine · Memphis, TNNPI 1356513394
Payments from drug & device makers
Across 689 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- GSK$582
- Boehringer Ingelheim$551
- Merck$533
- plus $3K from 33 others
What the payments were for
- Food & beverage$10,600100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 171 | $2,868 |
| AstraZeneca(2 entities) | 110 | $1,813 |
| Lilly USA, LLC | 113 | $1,509 |
| GSK | 41 | $582 |
| Boehringer Ingelheim | 35 | $551 |
| Merck | 41 | $533 |
| AbbVie(2 entities) | 30 | $478 |
| Pfizer | 24 | $342 |
| Bayer | 17 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $206 |
| Amarin Pharma, Inc. | 12 | $204 |
| Sanofi-aventis U.S. LLC | 11 | $152 |
| Ironwood Pharmaceuticals, Inc | 9 | $141 |
| Abbott | 6 | $106 |
| Johnson & Johnson | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Biohaven Pharmaceuticals, Inc. | 5 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Eisai Inc. | 3 | $49 |
| Amgen(2 entities) | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 3 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Ardelyx, Inc. | 2 | $29 |
| Exact Sciences | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Abiomed | 1 | $24 |
| Genentech USA, Inc. | 2 | $23 |
| Vivus LLC | 3 | $21 |
| Edwards Lifesciences | 1 | $21 |
| Cepheid | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| Gilead | 1 | $17 |
| Optos, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Recor Medical Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$101
How this compares
$10,620 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 37 | $72,932 |
| JardianceEmpagliflozin | 58 | $69,402 |
| FarxigaDapagliflozin Propanediol | 53 | $60,700 |
| OzempicSemaglutide | 29 | $40,277 |
| MounjaroTirzepatide | 28 | $38,850 |
| TrulicityDulaglutide | 17 | $27,228 |
| TradjentaLinagliptin | 17 | $24,423 |
| LinzessLinaclotide | 18 | $20,780 |
| EliquisApixaban | 24 | $19,452 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,297 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,520 |
| VascepaIcosapent Ethyl | 15 | $6,434 |
| PremarinEstrogens, Conjugated | 13 | $3,710 |
| SynthroidLevothyroxine Sodium | 27 | $2,644 |
| Atorvastatin Calcium | 248 | $2,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $2,868 | $113,21066 claims |
| Boehringer IngelheimJardiance, Tradjenta | $551 | $93,82475 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,509 | $66,07945 claims |
| AstraZenecaFarxiga | $1,813 | $60,70053 claims |
| AbbVieLinzess, Synthroid | $478 | $23,42345 claims |
| PfizerEliquis, Premarin | $342 | $23,16237 claims |
| GSKTrelegy Ellipta | $582 | $16,29718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Memphis
- Amanda MillerMemphis$171K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.